Beta Launch Saturday, 20 October 2018
Global Dow 3.79
2,835.68 0.13%
27 August 08:59 PM
S&P 500 4.08
2,443.05 0.17%
25 August 05:03 PM
EGX 23.25
12,949.65 0.18%
27 August 12:00 AM
TDWL -20.48
7,225.18 -0.28%
27 August 12:00 AM
DFM -21.94
3,602.55 -0.61%
27 August 12:00 AM
ADX -13.82
4,479.99 -0.31%
27 August 12:00 AM

Some cancers are 'born to be bad' - study

A groundbreaking study has uncovered why some patients' cancers are more deadly than others, despite appearing identical, the BBC reported.

Francis Crick Institute scientists developed a way of analyzing a cancer's history to predict its future.

The study on kidney cancer patients showed some tumors were "born to be bad" while others never became aggressive and may not need treating.

Cancer Research UK says the study could help patients get the best care.

"We don't really have tools to differentiate between those that need treatment and those that can be observed," said researcher and cancer doctor Samra Turajlic.

One cancer could kill quickly while a patient with a seemingly identical cancer could live for decades after treatment.

It means uncertainty for both the patient and the doctor.

The work, published in three papers in the journal Cell, analysed kidney cancers in 100 patients.

The team at the Crick performed a sophisticated feat of genetics to work out the cancer's history.

It works like a paternity or ancestry test on steroids.

As cancers grow and evolve, they become more mutated and, eventually, different parts of the tumor start to mutate in different ways.

Researchers take dozens of samples from different parts of the same tumor and then work out how closely related they are.

It allows scientists to piece together the evolutionary history of the whole tumor.

"That also tells us where the tumor might be heading as well," said Dr Turajlic.

The "born to be bad" tumours had rapid and extensive mutations and would grow so quickly they are likely to have spread round the body before they are even detected.

Surgery to remove the original tumour may delay the use of drugs that can slow the disease.

The benign tumours are at the complete opposite and are likely to grow so slowly they may never be a problem to patients and could just be monitored.

The intermediate tumors were likely to initially spread to just one other location in the body and could be treated with surgery.

RECOMMENDED

COMMENTS

There are no comments yet

LEAVE A COMMENT

Share with

My Account

Forgot password?

Create An Account

Forgot password?

Restore password

Subscribe to read
Already subscribed? Click here

For a limited time!
12 Months = 15 Months
24 Months = 32 Months
(Included Postal Fees worldwide)

Read, Explore Opportunities
Be connected with Business, Investment, Finance, Stock Exchange, Currencies, Development and International Cooperation

3 Months

18 USD / 60 AED

English Edition

Subscribe

3 Months

18 USD / 60 AED

Arabic Edition

Subscribe

3 Months

29.9 USD / 99 AED

Both Editions

Subscribe

6 Months

36 USD / 120 AED

English Edition

Subscribe

6 Months

36 USD / 120 AED

Arabic Edition

Subscribe

6 Months

59.9 USD / 199 AED

Both Editions

Subscribe

12 Months

72 USD / 240 AED

English Edition
Good Deal! 
(15 Months instead of 12 Months)

Subscribe

12 Months

72 USD / 240 AED

Arabic Edition
Good Deal! 
(15 Months instead of 12 Months)

Subscribe

12 Months

122 USD / 408 AED

Both Editions
Good Deal! 
(15 Months instead of 12 Months)

Subscribe

24 Months

144 USD / 480 AED

English Edition
Amazing Deal!
(32 Months instead of 24 Months)

Subscribe

24 Months

144 USD / 480 AED

Arabic Edition
Amazing deal!
(32 Months instead of 24 Months)

Subscribe

24 Months

240 USD / 799 AED

Both Editions
Amazing deal!
(32 Months instead of 24 Months)

Subscribe
* Terms and conditions apply.